对移植接受者进行抗肥胖药物治疗
Christine E Haugen1, Babak J Orandi2
1Department of Surgery, University of Cincinnati, Cincinnati, OH, USA.
Current atherosclerosis reports
|January 23, 2026
概括
抗肥胖药物,包括营养刺激激素 (NuSH) 激动剂,对移植接受者来说是有希望的. 需要进一步的研究来指导它们的使用,并改善这种高风险人群的长期存活率.
科学领域:
- 移植医学 移植医学
- 药理学 药理学是指药理学的学科.
- 肥胖管理 肥胖管理
背景情况:
- 在肝脏 (高达40%) 和脏 (33%) 移植受体中,肥胖很普遍.
- 移植后体重增加很常见,并且与较差的结果有关,包括减少全移植生存率和增加心血管风险.
- 尽管有很高的需求,但在移植人群中,抗肥胖药物治疗的使用是有限的.
研究的目的:
- 审查肝脏和脏移植接受者的抗肥胖药物治疗选择.
- 为了指导在这个特定的患者群体中使用这些药物.
主要方法:
- 审查当前的抗肥胖药物治疗选择.
- 对移植受体药物使用现有数据的分析.
主要成果:
- 营养刺激激素 (NuSH) 药物,如葡萄糖类-1 (GLP-1) 受体激动剂和双GLP-1/依赖葡萄糖的胰岛素型多 (GIP) 受体激动剂,对一般人群的肥胖和心血管风险降低是有效的.
- 这些药物对治疗移植患者的肥胖有兴趣.
- 有限的数据存在于肝脏和脏移植接受者的有效性和安全性.
结论:
- 抗肥胖药物,特别是NuSH激动剂,可能会为移植接受者带来好处.
- 进一步的研究,包括随机对照试验,至关重要.
- 将肥胖药物专业知识整合到常规移植护理中,对于改善长期移植和患者生存至关重要.
相关概念视频
Psychosis: Goals of Pharmacotherapy
480
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
480
Diabetes: Management and Pharmacotherapy
883
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
883
Obesity
1.2K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.2K
Drug Dosing: Obese Patients
238
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
238
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
260
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
260
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
175
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
175


